RxDoctor Payments Data

Dorian Jones, MD

Gastroenterology · East Lansing, MINPI 1508157702

Payments from drug & device makers

$11,592in general payments, 2019–2025

Across 687 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Johnson & Johnson$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Pfizer$585
  • Gilead$564
  • plus $3K from 30 others

What the payments were for

  • Food & beverage$11,41698%
  • Education$1762%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,592 in reported general payments places this provider in the 75th percentile of 497 gastroenterology providers in Michigan.

See all gastroenterology providers in Michigan

Medicare billing

Part B allowed, 2024
$129,239
Medicare patients
317
Services billed
3,607

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab53$1,443,625
Humira(Cf) PenAdalimumab15$100,692
XeljanzTofacitinib Citrate14$76,546
Cimzia (2 Pack)Certolizumab Pegol12$64,438
LinzessLinaclotide21$15,320
SutabSod Sulf/Pot Chloride/Mag Sulf65$10,349
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl175$3,626
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl126$2,558
Pantoprazole Sodium71$1,940
Budesonide DrBudesonide11$1,272
Omeprazole55$920
Dicyclomine Hcl13$477
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine13$437

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,377$1,443,62553 claims
PfizerXeljanz$585$76,54614 claims
UCB, Inc.Cimzia (2 Pack)$28$64,43812 claims
AbbVieLinzess$2,547$15,32021 claims
Braintree Laboratories, Inc.Sutab$73$10,34965 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 497 gastroenterology providers in Michigan.

Other gastroenterology in East Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →